Bio-Techne (TECH) Stock Forecast, Price Target & Predictions
TECH Stock Forecast
Bio-Techne stock forecast is as follows: an average price target of $91.69 (represents a 29.05% upside from TECH’s last price of $71.05) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
TECH Price Target
The average price target for Bio-Techne (TECH) is $91.69 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $105.00 to $80.00. This represents a potential 29.05% upside from TECH's last price of $71.05.
TECH Analyst Ratings
According to 7 Wall Street analysts, Bio-Techne's rating consensus is 'Buy'. The analyst rating breakdown for TECH stock is 0 'Strong Buy' (0.00%), 4 'Buy' (57.14%), 2 'Hold' (28.57%), 1 'Sell' (14.29%), and 0 'Strong Sell' (0.00%).
Bio-Techne Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 31, 2024 | Catherine Schulte | Robert W. Baird | $84.00 | $76.02 | 10.50% | 18.23% |
| Oct 30, 2024 | Paul Knight | KeyBanc | $80.00 | $76.02 | 5.24% | 12.60% |
| Aug 16, 2024 | Sung Ji Nam | Scotiabank | $83.00 | $74.19 | 11.87% | 16.82% |
| Dec 14, 2022 | - | Deutsche Bank | $100.00 | $86.98 | 14.97% | 40.75% |
| Dec 12, 2022 | - | Citigroup | $100.00 | $80.73 | 23.87% | 40.75% |
| Dec 07, 2022 | - | RBC Capital | $89.00 | $80.67 | 10.33% | 25.26% |
| Dec 05, 2022 | - | Stephens | $105.00 | $82.44 | 27.37% | 47.78% |
| May 05, 2022 | Paul Knight | KeyBanc | $125.00 | $98.96 | 26.31% | 75.93% |
| Apr 25, 2022 | - | Wells Fargo | $92.50 | $100.75 | -8.19% | 30.19% |
| May 06, 2021 | Patrick B Donnelly | Citigroup | $106.25 | $102.45 | 3.71% | 49.54% |
The latest Bio-Techne stock forecast, released on Oct 31, 2024 by Catherine Schulte from Robert W. Baird, set a price target of $84.00, which represents a 10.50% increase from the stock price at the time of the forecast ($76.02), and a 18.23% increase from TECH last price ($71.05).
Bio-Techne Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 2 | 3 |
| Avg Price Target | $82.00 | $82.00 | $82.33 |
| Last Closing Price | $71.05 | $71.05 | $71.05 |
| Upside/Downside | 15.41% | 15.41% | 15.88% |
In the current month, the average price target of Bio-Techne stock is $82.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 15.41% increase as opposed to Bio-Techne's last price of $71.05. This month's average price target is down 0.00% compared to last quarter, and down -0.40% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 30, 2024 | KeyBanc | Overweight | Overweight | Hold |
| Aug 16, 2024 | Scotiabank | Sector Outperform | Sector Outperform | Hold |
| Aug 13, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| May 22, 2024 | Deutsche Bank | Buy | Buy | Hold |
| May 22, 2024 | Citigroup | Buy | Neutral | Downgrade |
| May 02, 2024 | Scotiabank | Outperform | Outperform | Hold |
| Feb 02, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Aug 28, 2023 | William Blair | - | Outperform | Initialise |
| Dec 14, 2022 | Deutsche Bank | - | Buy | Initialise |
| Dec 12, 2022 | Citigroup | - | Buy | Upgrade |
Bio-Techne's last stock rating was published by KeyBanc on Oct 30, 2024. The company gave TECH a "Overweight" rating, the same as its previous rate.
Bio-Techne Financial Forecast
Bio-Techne Revenue Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $272.60M | $276.94M | $301.32M | $294.15M | $271.58M | $269.65M | $288.23M | $290.38M | $269.28M | $257.72M | $259.03M | $243.55M | $224.25M | $204.20M | $175.83M | $194.68M |
| Avg Forecast | $400.43M | $383.42M | $347.75M | $345.50M | $359.12M | $346.71M | $312.99M | $312.98M | $328.78M | $318.23M | $286.14M | $280.22M | $306.49M | $292.15M | $277.55M | $287.66M | $307.22M | $296.61M | $288.80M | $281.83M | $286.71M | $279.27M | $266.44M | $252.78M | $244.65M | $228.22M | $206.50M | $185.03M | $163.91M | $185.93M |
| High Forecast | $405.35M | $388.13M | $352.02M | $349.74M | $363.53M | $350.97M | $316.83M | $316.82M | $332.82M | $320.18M | $288.39M | $281.67M | $306.49M | $292.25M | $285.67M | $292.69M | $310.99M | $300.25M | $292.34M | $281.83M | $286.71M | $279.27M | $266.44M | $252.78M | $244.65M | $228.22M | $206.50M | $185.03M | $163.91M | $185.93M |
| Low Forecast | $396.03M | $379.21M | $343.93M | $341.71M | $355.18M | $342.90M | $309.55M | $309.54M | $325.17M | $316.84M | $283.30M | $278.77M | $306.49M | $292.05M | $271.57M | $282.89M | $303.84M | $293.35M | $285.62M | $281.83M | $286.71M | $279.27M | $266.44M | $252.78M | $244.65M | $228.22M | $206.50M | $185.03M | $163.91M | $185.93M |
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 8 | 4 | 4 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 7 | 7 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.98% | 0.96% | 0.98% | 0.99% | 0.94% | 0.96% | 1.01% | 1.04% | 1.01% | 1.02% | 1.06% | 1.07% | 1.09% | 1.10% | 1.07% | 1.05% |
Bio-Techne's average Quarter revenue forecast for Mar 24 based on 4 analysts is $292.15M, with a low forecast of $292.05M, and a high forecast of $292.25M. TECH's average Quarter revenue forecast represents a 7.17% increase compared to the company's last Quarter revenue of $272.60M (Dec 23).
Bio-Techne EBITDA Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 8 | 4 | 4 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 7 | 7 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $38.00M | $84.40M | $121.45M | $107.18M | $94.59M | $82.96M | $106.44M | $115.81M | $122.30M | $96.16M | $35.39M | $69.50M | $80.97M | $64.84M | $87.13M | $72.42M |
| Avg Forecast | $148.22M | $141.93M | $128.72M | $127.89M | $132.93M | $128.34M | $115.86M | $115.85M | $121.70M | $117.79M | $105.92M | $103.73M | $113.45M | $100.87M | $102.74M | $106.48M | $113.72M | $91.70M | $127.76M | $84.53M | $86.00M | $83.37M | $79.92M | $75.82M | $73.38M | $58.74M | $61.94M | $55.50M | $49.16M | $57.30M |
| High Forecast | $150.04M | $143.67M | $130.30M | $129.46M | $134.57M | $129.91M | $117.28M | $117.27M | $123.20M | $118.52M | $106.75M | $104.26M | $113.45M | $121.05M | $105.74M | $108.34M | $115.12M | $110.04M | $153.32M | $84.53M | $86.00M | $100.04M | $79.92M | $75.82M | $73.38M | $70.48M | $61.94M | $55.50M | $49.16M | $68.76M |
| Low Forecast | $146.59M | $140.37M | $127.31M | $126.49M | $131.47M | $126.93M | $114.58M | $114.58M | $120.36M | $117.28M | $104.86M | $103.19M | $113.45M | $80.70M | $100.52M | $104.72M | $112.47M | $73.36M | $102.21M | $84.53M | $86.00M | $66.69M | $79.92M | $75.82M | $73.38M | $46.99M | $61.94M | $55.50M | $49.16M | $45.84M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.37% | 0.79% | 1.07% | 1.17% | 0.74% | 0.98% | 1.24% | 1.39% | 1.53% | 1.27% | 0.48% | 1.18% | 1.31% | 1.17% | 1.77% | 1.26% |
4 analysts predict TECH's average Quarter EBITDA for Mar 24 to be $100.87M, with a high of $121.05M and a low of $80.70M. This is 165.43% upper than Bio-Techne's previous annual EBITDA (Dec 23) of $38.00M.
Bio-Techne Net Income Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 8 | 4 | 4 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 7 | 7 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $27.46M | $50.99M | $75.48M | $70.22M | $50.01M | $89.56M | $61.52M | $60.74M | $72.06M | $69.61M | $14.96M | $45.78M | $46.27M | $33.40M | $58.84M | $36.43M |
| Avg Forecast | $113.51M | $103.61M | $84.46M | $84.98M | $100.66M | $94.68M | $74.72M | $75.94M | $89.16M | $82.93M | $62.17M | $61.49M | $79.74M | $64.67M | $66.41M | $70.03M | $88.05M | $58.80M | $83.76M | $73.52M | $83.39M | $53.45M | $71.88M | $69.15M | $68.33M | $38.69M | $55.03M | $44.37M | $30.23M | $28.83M |
| High Forecast | $115.32M | $105.27M | $85.81M | $86.34M | $102.26M | $96.19M | $75.91M | $77.15M | $90.58M | $84.26M | $65.45M | $62.16M | $79.74M | $77.61M | $71.15M | $76.40M | $89.46M | $70.55M | $100.51M | $73.52M | $83.39M | $64.14M | $71.88M | $69.15M | $68.33M | $46.43M | $55.03M | $44.37M | $30.23M | $34.59M |
| Low Forecast | $111.88M | $102.13M | $83.25M | $83.77M | $99.22M | $93.33M | $73.65M | $74.86M | $87.88M | $81.34M | $60.54M | $60.82M | $79.73M | $51.74M | $61.67M | $65.26M | $86.79M | $47.04M | $67.00M | $73.52M | $83.39M | $42.76M | $71.88M | $69.15M | $68.33M | $30.95M | $55.03M | $44.37M | $30.23M | $23.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.41% | 0.73% | 0.86% | 1.19% | 0.60% | 1.22% | 0.74% | 1.14% | 1.00% | 1.01% | 0.22% | 1.18% | 0.84% | 0.75% | 1.95% | 1.26% |
Bio-Techne's average Quarter net income forecast for Mar 24 is $64.67M, with a range of $51.74M to $77.61M. TECH's average Quarter net income forecast represents a 135.48% increase compared to the company's last Quarter net income of $27.46M (Dec 23).
Bio-Techne SG&A Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 8 | 4 | 4 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 7 | 7 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $115.67M | $105.33M | $86.75M | $99.24M | $93.01M | $99.38M | $96.63M | $89.27M | $100.69M | $86.17M | $51.61M | $82.60M | $83.12M | $72.60M | $65.80M | $66.32M |
| Avg Forecast | $142.09M | $136.05M | $123.40M | $122.60M | $127.43M | $123.03M | $111.06M | $111.06M | $116.66M | $112.92M | $101.54M | $99.43M | $108.75M | $95.05M | $98.48M | $102.07M | $109.01M | $86.41M | $105.19M | $97.91M | $99.61M | $78.56M | $92.57M | $87.82M | $85.00M | $69.81M | $71.74M | $64.28M | $56.95M | $52.48M |
| High Forecast | $143.83M | $137.72M | $124.91M | $124.10M | $129.00M | $124.54M | $112.43M | $112.42M | $118.10M | $113.61M | $102.33M | $99.95M | $108.75M | $114.06M | $101.37M | $103.86M | $110.35M | $103.69M | $126.23M | $97.91M | $99.61M | $94.27M | $92.57M | $87.82M | $85.00M | $83.77M | $71.74M | $64.28M | $56.95M | $62.97M |
| Low Forecast | $140.53M | $134.56M | $122.04M | $121.25M | $126.03M | $121.67M | $109.84M | $109.84M | $115.38M | $112.43M | $100.52M | $98.92M | $108.75M | $76.04M | $96.36M | $100.38M | $107.82M | $69.13M | $84.15M | $97.91M | $99.61M | $62.85M | $92.57M | $87.82M | $85.00M | $55.85M | $71.74M | $64.28M | $56.95M | $41.98M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.17% | 1.03% | 0.80% | 1.15% | 0.88% | 1.01% | 0.97% | 1.14% | 1.09% | 0.98% | 0.61% | 1.18% | 1.16% | 1.13% | 1.16% | 1.26% |
Bio-Techne's average Quarter SG&A projection for Mar 24 is $95.05M, based on 4 Wall Street analysts, with a range of $76.04M to $114.06M. The forecast indicates a -17.82% fall compared to TECH last annual SG&A of $115.67M (Dec 23).
Bio-Techne EPS Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 8 | 4 | 4 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 7 | 7 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.17 | $0.32 | $0.48 | $0.45 | $0.32 | $0.57 | $0.39 | $0.39 | $0.46 | $0.42 | $0.09 | $0.28 | $0.29 | $0.21 | $0.37 | $0.23 |
| Avg Forecast | $0.70 | $0.64 | $0.52 | $0.53 | $0.62 | $0.59 | $0.46 | $0.47 | $0.55 | $0.51 | $0.39 | $0.38 | $0.49 | $0.45 | $0.41 | $0.43 | $0.55 | $0.53 | $0.49 | $0.46 | $0.52 | $0.50 | $0.45 | $0.43 | $0.43 | $0.39 | $0.34 | $0.28 | $0.19 | $0.29 |
| High Forecast | $0.72 | $0.65 | $0.53 | $0.54 | $0.63 | $0.60 | $0.47 | $0.48 | $0.56 | $0.52 | $0.41 | $0.39 | $0.49 | $0.45 | $0.44 | $0.47 | $0.56 | $0.54 | $0.50 | $0.46 | $0.52 | $0.50 | $0.45 | $0.43 | $0.43 | $0.39 | $0.34 | $0.28 | $0.19 | $0.29 |
| Low Forecast | $0.69 | $0.63 | $0.52 | $0.52 | $0.62 | $0.58 | $0.46 | $0.46 | $0.55 | $0.50 | $0.38 | $0.38 | $0.49 | $0.45 | $0.38 | $0.41 | $0.54 | $0.52 | $0.48 | $0.46 | $0.52 | $0.50 | $0.45 | $0.43 | $0.43 | $0.39 | $0.34 | $0.28 | $0.19 | $0.29 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.41% | 0.74% | 0.88% | 0.85% | 0.66% | 1.25% | 0.75% | 0.78% | 1.03% | 0.98% | 0.21% | 0.73% | 0.84% | 0.76% | 1.97% | 0.80% |
According to 4 Wall Street analysts, Bio-Techne's projected average Quarter EPS for Mar 24 is $0.45, with a low estimate of $0.45 and a high estimate of $0.45. This represents a 166.34% increase compared to TECH previous annual EPS of $0.17 (Dec 23).
Bio-Techne Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $1.73 | $33.86 | 1857.23% | Buy |
| APLS | Apellis Pharmaceuticals | $27.75 | $74.50 | 168.47% | Buy |
| REPL | Replimune Group | $11.05 | $24.20 | 119.00% | Buy |
| LEGN | Legend Biotech | $39.75 | $82.69 | 108.03% | Buy |
| LQDA | Liquidia | $10.15 | $17.17 | 69.16% | Buy |
| BMRN | BioMarin Pharmaceutical | $63.45 | $101.70 | 60.28% | Buy |
| ASND | Ascendis Pharma | $122.64 | $190.21 | 55.10% | Buy |
| AKRO | Akero Therapeutics | $31.20 | $46.00 | 47.44% | Buy |
| PCVX | Vaxcyte | $88.39 | $124.00 | 40.29% | Buy |
| BGNE | BeiGene | $194.56 | $255.80 | 31.48% | Buy |
| TECH | Bio-Techne | $71.05 | $91.69 | 29.05% | Buy |
| HALO | Halozyme Therapeutics | $45.70 | $57.00 | 24.73% | Buy |
| NUVL | Nuvalent | $92.73 | $111.57 | 20.32% | Buy |
| TVTX | Travere Therapeutics | $18.26 | $21.75 | 19.11% | Buy |
| BPMC | Blueprint Medicines | $96.62 | $109.71 | 13.55% | Buy |
| ALNY | Alnylam Pharmaceuticals | $246.80 | $254.21 | 3.00% | Buy |
| UTHR | United Therapeutics | $367.36 | $358.20 | -2.49% | Buy |
| EXEL | Exelixis | $34.83 | $30.50 | -12.43% | Buy |